Related Experiment Video
Updated: Sep 9, 2026
Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
Published on: July 12, 2024
Association between air pollution, multimorbidity and polypharmacy: a systematic review and meta-analysis
Hanbin Zhang1,2, Abiola Rodemade3,4, Siyu Wang1
1European Centre for Environment and Human Health, University of Exeter Medical School, Exeter, UK.
Objectives:
To comprehensively examine the existing literature investigating the association between air pollution exposure and multimorbidity and/or polypharmacy.
Design:
Systematic review and meta-analysis.
Data Sources:
PubMed, Web of Science, EMBASE and the Cochrane Library.
Eligibility Criteria:
Observational studies assessed the association between air pollution and the risk of multimorbidity and/or polypharmacy among the general population were searched. Only full-text original human studies written in English up to 1 April 2026 were included.
Data Extraction And Synthesis:
Data was extracted using a standardised data extraction template and analysed using Stata SE V.19. Estimates were pooled using a random effects model, with the I 2 statistic used to estimate heterogeneity of results (PROSPERO registration: CRD42024613048).
Results:
In total, 22 studies met the inclusion criteria in our systematic review and 21 of 22 were included for meta-analysis. After excluding incompatible effect estimates (increment other than per 5 µg/m3, 10 µg/m3 or IQR increase) and studies using overlapping datasets, four, three, two and four were included in the main meta-analysis, respectively, with a pooled adjusted risk ratio (aRR) of 1.15 (95% CI 1.08 to 1.23; I 2 =93.0%) per 5 µg/m³ particulate matter (PM)2.5 increase, a pooled aRR of 1.27 (95% CI 1.11 to 1.47; I 2 =99.5%) per 5 µg/m³ PM10 increase, a pooled aRR of 1.07 (95% CI 1.05 to 1.09; I 2 =0.0%) per 5 µg/m³ PM1 increase and a pooled aRR of 1.12 (95% CI 1.00 to 1.26; I 2 =96.6%) per 5 µg/m³ nitrogen dioxide (NO2) increase. There was no evidence of associations between other air pollutants (nitrogen oxides (N=3), black carbon (N=1), sulphur dioxide (N=3), ozone (N=4), carbon monoxide (N=3)) and multimorbidity. No eligible studies on polypharmacy, indoor air pollution, older adults, American and Oceanian populations were identified.
Conclusions:
Long-term exposure to ambient PM2.5 and NO2 may elevate the risk of multimorbidity. Future research should prioritise household air pollution, rural areas, older populations as a target group, continents other than Europe and Asia and polypharmacy.
Related Concept Videos
01:24Drug Toxicity: Risk factors
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
01:27Pharmacogenetics of Drug Metabolism: Overview
01:23Chronic Obstructive Pulmonary Disease I: Introduction